Ohio is currently home to 3204 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Cincinnati, Columbus, Cleveland and Dayton. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
Evaluation of Efficacy and Safety of VX-993 for Pain Associated With Diabetic Peripheral Neuropathy
NCT06619860
Recruiting
The purpose of this study is to evaluate the efficacy, safety, and tolerability of VX-993 in participants with pain associated with Diabetic Peripheral Neuropathy (DPN)
Gender:
ALL
Ages:
Between 18 years and 80 years
Trial Updated:
07/15/2025
Locations: Velocity Clinical Research - Cleveland, Beachwood, Ohio
Conditions: Diabetic Peripheral Neuropathic Pain
Register for Updates
A Study to Evaluate ALN-BCAT in Patients With Hepatocellular Carcinoma
NCT06600321
Recruiting
The purpose of the dose escalation part of the study is to characterize the safety and tolerability of ALN-BCAT as monotherapy and in combination with pembrolizumab; and to determine the recommended dose(s) for expansion (RDFE) of ALN-BCAT as monotherapy and in combination with pembrolizumab. The purpose of the dose expansion part of the of the study is to evaluate the antitumor activity of ALN-BCAT as monotherapy and in combination with pembrolizumab; to characterize the safety and tolerability... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/15/2025
Locations: Clinical Trial Site, Cleveland, Ohio
Conditions: Advanced Hepatocellular Carcinoma, Metastatic Hepatocellular Carcinoma
Register for Updates
Phase 2 Study to Evaluate Safety and Efficacy of Cretostimogene Grenadenorepvec in High-Risk NMIBC
NCT06567743
Recruiting
This is a Phase 2, Multi-Arm, Multi-Cohort, Open-Label Study to Evaluate the Safety and Efficacy of Cretostimogene Grenadenorepvec in Participants with High-Risk Non-Muscle-Invasive Bladder Cancer.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/15/2025
Locations: The Urology Group (Solaris), Cincinnati, Ohio
Conditions: High-Risk Non-Muscle-Invasive Bladder Cancer
Register for Updates
Study of RAS(ON) Inhibitors in Patients With Gastrointestinal Solid Tumors
NCT06445062
Recruiting
The purpose of this platform study is to evaluate the safety, tolerability, pharmacokinetics (PK), and preliminary antitumor activity of novel RAS(ON) inhibitors combined with Standard(s) of Care (SOC) or with novel agents. The current subprotocols include the following: Subprotocol A: RMC-6236 + 5-fluorouracil-based regimens Subprotocol B: RMC-6236 + cetuximab with or without mFOLFOX6 Subprotocol C: RMC-6236 + gemcitabine + nab-paclitaxel Subprotocol D: RMC-9805 with or without RMC-6236 +... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/15/2025
Locations: University of Cincinnati Medical Center, Cincinnati, Ohio
Conditions: Colorectal Cancer, CRC, Pancreatic Ductal Adenocarcinoma, PDAC, Gastrointestinal Cancer, Metastatic Pancreatic Ductal Adenocarcinoma
Register for Updates
A Study Comparing Anitocabtagene Autoleucel to Standard of Care Therapy in Participants With Relapsed/ Refractory Multiple Myeloma
NCT06413498
Recruiting
The goal of this study (iMMagine-3) is to compare the study drug, anitocabtagene autoleucel to standard of care therapy (SOCT) in participants with relapsed/refractory multiple myeloma who have received 1 to 3 prior lines of therapy, including an anti-CD38 monoclonal antibody and an immunomodulatory drug. The primary objective of this study is to compare the efficacy of anitocabtagene autoleucel versus SOCT in participants with RRMM.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/15/2025
Locations: University of Cincinnati Medical Center, Cincinnati, Ohio
Conditions: Multiple Myeloma
Register for Updates
A Phase 2 Trial of ALN-APP in Patients With Cerebral Amyloid Angiopathy
NCT06393712
Recruiting
The purpose of the study is to evaluate the effect of ALN-APP on measures of CAA disease progression and to characterize the safety, tolerability, and pharmacodynamics (PD) of ALN-APP in adult patients with sporadic CAA (sCAA) and Dutch-type CAA (D-CAA). The study will be conducted over 2 periods: a 24-month double-blind treatment period and an optional 18-month open-label extension (OLE) period. The estimated duration of study participation, inclusive of screening, treatment, and additional saf... Read More
Gender:
ALL
Ages:
30 years and above
Trial Updated:
07/15/2025
Locations: Clinical Trial Site, Canton, Ohio
Conditions: Cerebral Amyloid Angiopathy
Register for Updates
A Study of Lebrikizumab (LY3650150) in Adult Participants With Chronic Rhinosinusitis and Nasal Polyps Treated With Intranasal Corticosteroids (CONTRAST-NP)
NCT06338995
Recruiting
The main purpose of this study is to evaluate the efficacy and safety of lebrikizumab in adult participants with chronic rhinosinusitis and nasal polyps treated with intranasal corticosteroids. The study will last about 18 months.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/15/2025
Locations: UCMC, Cincinnati, Ohio
Conditions: Chronic Rhinosinusitis With Nasal Polyps (CRSwNP)
Register for Updates
MicroRNAs as Biomarkers for Obstructive Sleep Apnea
NCT06189755
Recruiting
Although obstructive sleep apnea (OSA) is a common disorder, there are no blood biomarkers for identification and management of these patients. This project will study microRNAs in order to develop and validate blood biomarkers that are specific to OSA, useful for identification of cases with OSA, reflective of efficacy of therapy, and able to predict blood pressure response to treatment of OSA.
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
07/15/2025
Locations: The Ohio State University - Martha Morehouse Medical Pavilion, Suite 2600, Columbus, Ohio
Conditions: Obstructive Sleep Apnea
Register for Updates
A Randomized Comparison of Stage-Based Care Versus Risk Factor-Based Care for Prevention of Cardiovascular Events
NCT06112418
Recruiting
TRANSFORM is a prospective, randomized, open blinded endpoint (PROBE), event-driven, pragmatic trial in patients who are at increased risk for atherosclerotic cardiovascular (CV) disease but with no known symptomatic CV disease. The trial tests the hypothesis that a Cleerly Coronary Artery Disease (CAD) Staging System-based care strategy reduces CV events compared with risk factor-based care.
Gender:
ALL
Ages:
55 years and above
Trial Updated:
07/15/2025
Locations: Summa Health, Akron, Ohio
Conditions: Diabetes Mellitus, Type 2, PreDiabetes, Metabolic Syndrome
Register for Updates
The PEERLESS II Study
NCT06055920
Recruiting
This study is a prospective, multicenter, randomized controlled trial of the FlowTriever System plus anticoagulation compared to anticoagulation alone for intermediate-risk acute PE.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/15/2025
Locations: University of Cincinnati Medical Center, Cincinnati, Ohio
Conditions: Pulmonary Embolism
Register for Updates
CTSN Embolic Protection Trial
NCT06027788
Recruiting
This is a prospective, multi-center, randomized effectiveness trial of the CardioGard Embolic Protection Cannula in high-risk valve surgery patients.
Gender:
ALL
Ages:
60 years and above
Trial Updated:
07/15/2025
Locations: University Hospitals, Cleveland, Ohio
Conditions: Delirium, Ischemic Stroke, Acute Kidney Injury, Heart Valve Disease, Coronary Artery Disease
Register for Updates
Study of Ribociclib and Everolimus in HGG and DIPG
NCT05843253
Recruiting
The goal of this study is to determine the efficacy of the study drugs ribociclib and everolimus to treat pediatric and young adult patients newly diagnosed with a high-grade glioma (HGG), including DIPG, that have genetic changes in pathways (cell cycle, PI3K/mTOR) that these drugs target. The main question the study aims to answer is whether the combination of ribociclib and everolimus can prolong the life of patients diagnosed with HGG, including DIPG.
Gender:
ALL
Ages:
Between 12 months and 39 years
Trial Updated:
07/15/2025
Locations: Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio
Conditions: High Grade Glioma, Diffuse Intrinsic Pontine Glioma, Anaplastic Astrocytoma, Glioblastoma, Glioblastoma Multiforme, Diffuse Midline Glioma, H3 K27M-Mutant, Metastatic Brain Tumor, WHO Grade III Glioma, WHO Grade IV Glioma
Register for Updates